Asia Regenerative Medicine
Latest round
- Series A
Last raised
- Oct 2025
Total raised
- Undisclosed
Investors
- 1
About Asia Regenerative Medicine
Established in 2018 and based in Shenzhen, China, Asia Regenerative Medicine is a company that prepares implantable bio-artificial organs with stem cell and tissue engineering device technology as the core. The company was founded by several medical experts, transplant physicians and university professors, and collaborated to introduce projects from Harvard University and University of Toronto Medical School. The company is headquartered in Shenzhen, with cell and material laboratories in Guangzhou, Wuhan and Hong Kong, and joint polymer material and cell laboratories in Shanghai University and Sun Yat-sen University. The Company's products include iPS-induced differentiated renal progenitor cells, urine-derived renal precursor cells, in vitro artificial kidneys, and implantable artificial kidneys for the treatment of nephropathy, and iPS/ES-induced differentiated pancreatic islet cells, and biosynthesized artificial pancreas for diabetes. The company generates revenue through providing stem cell and tissue engineering technologies to develop stem cells, exosomes, drugs, dialysis enhancement, and manufacture implantable bioartificial kidneys for kidney diseases, aiming to solve the problems of kidney CKD functional decline, end-stage diseases, and organ transplant shortages.
Who invested in Asia Regenerative Medicine
1 investor across 1 round
See all investors in Asia Regenerative Medicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 30, 2025
Amount
Undisclosed
Investors
Questions about Asia Regenerative Medicine
Who invested in Asia Regenerative Medicine?
Asia Regenerative Medicine has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Asia Regenerative Medicine raised?
Asia Regenerative Medicine has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Asia Regenerative Medicine last raise money?
Asia Regenerative Medicine's most recent round on record is a Series A, in Oct 2025.
What does Asia Regenerative Medicine do?
Established in 2018 and based in Shenzhen, China, Asia Regenerative Medicine is a company that prepares implantable bio-artificial organs with stem cell and tissue engineering device technology as the core.
Where is Asia Regenerative Medicine headquartered?
Asia Regenerative Medicine is headquartered in Shenzhen, China.
Which VCs invest in companies like Asia Regenerative Medicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Asia Regenerative Medicine's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Asia Regenerative Medicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.